Neuropathic pain is a condition which involves pain caused due to damage or diseases affecting the nervous system. These conditions may include diseases such as diabetes causing diabetic neuropathy, chemotherapy induced neuropathic pain, and trigeminal neuralgia. Diabetic neuropathy is the damage caused to the nerve due to diabetes, which often leads to pain and numbness in feet or lower legs. The pain can be experienced in other parts of the body such as hips, wrist and back depending upon the effect of neuropathy. There are different types of neuropathy such as focal neuropathy, proximal neuropathy, peripheral neuropathy and autonomic neuropathy. According to data published on Up to Date journal on December 2022, an estimated 50% of diabetic population suffers from diabetic neuropathy across the globe. Further, as per CDC estimates, 6-7 people per 1000 diabetic population suffer from diabetic neuropathy in the U.S.
Market Dynamics
The key market players are focusing on adoption of growth strategies such as research and development activities, clinical trials, acquisitions and launch of newer products, which is attributed to the growth of global neuropathic pain market. For instance, on November 16, 2021, Francesco Bono a university started phase 2 study of BoNT-A for the neurogenic inflammation and neuropathic pain. The drug is under the clinical trial in phase 2, study starts on May 25, 2030 and expected to complete by December 2023.
Key features of the study:
- This report provides an in-depth analysis of the global neuropathic pain market and provides market size (US$ Billion) and compound annual growth rate (CAGR) for the forecast period (2023–2030), considering 2022 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global neuropathic pain market based on the following parameters–Company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Pfizer, Inc., Johnson & Johnson Services, Inc., Sanofi S.A., Eily Lily and Company, GlaxoSmithKline PLC, Biogen Idec., Bristol-Myers Squibb, Baxter Healthcare Corporation, and Depomed, Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global neuropathic pain market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global neuropathic pain market.
Detailed Segmentation:
- Global Neuropathic Pain Market, By Drug Class:
- Tricyclic Anti-Depressant
- Anticonvulsant
- Local Anaesthesia
- Opioids
- Steroids
- Others
- Global Neuropathic Pain Market, By Indication:
- Diabetic neuropathy
- Chemotherapy-induced Peripheral neuropathy
- Other
- Global Neuropathic Pain Market, By Distribution Channel:
- Retail Pharmacies
- Drug Store
- Online Pharmacies
- Global Neuropathic Pain Market, By Geography:
- North America
- Europe
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East:
- GCC
- Israel
- Rest of Middle East
- Africa
- Central Africa
- South Africa
- North Africa
- Company Profiles
- Pfizer, Inc.
- Johnson & Johnson Services, Inc.
- Sanofi S.A.
- Eily Lily and Company
- GlaxoSmithKline PLC
- Biogen Idec.
- Bristol-Myers Squibb
- Baxter Healthcare Corporation
- Depomed, Inc.
